touchONCOLOGY - Online Education for Oncology Professionals

Time 2021-04-26 09:07:49

Web Name: touchONCOLOGY - Online Education for Oncology Professionals

WebSite: http://www.touchoncology.com

ID:172352

Keywords:

Education,Online,touchONCOLOGY,

Description:

Trending Across touchONCOLOGY At a glance: education, conference reports and articles Gynaecological Oncology, Ovarian Cancer touchCONGRESS PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice Dr Alexandra Leary, Prof. Keiichi Fujiwara, Prof. Nicoletta Colombo Watch Time: 61 mins Available in: Watch this two-part activity exploring recent developments on the use of PARP inhibitors as first-line maintenance therapy in ovarian cancer. Filmed following the SGO Virtual Annual Meeting 2021.Part 1: Watch gynaecological cancer expert Dr Alexandra Leary review key data from the SGO Virtual Annual Meeting 2021 Watch NowPart 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview Learning objectives Learning Objectives Recall the latest data for PARP inhibitors for first-line maintenance treatment and how they may impact clinical practice Describe the latest safety data for the PARP inhibitors Define the different factors that influence treatment selection of PARP inhibitor therapy in the first-line maintenance setting View All Immunotherapy, Lung Cancer touchPANEL DISCUSSION Targeting IL-1β in NSCLC: What does the future hold? Dr Pilar Garrido, Dr Barbara Melosky, Dr Alastair Greystoke Watch Time: 30 mins Available in: Watch a panel of experts discuss immunotherapy for non-small cell lung cancer (NSCLC) and the possible future role of interleukin-1β (IL-1β) blockade. Learning objectives Learning Objectives Discuss the use of checkpoint inhibitors as immunotherapy for NSCLC and recognize their limitations Recall the rationale for targeting IL-1β in cancer immunotherapy and the IL-1β-targeted agents currently in clinical development for solid tumours Describe the clinical trials and data for IL-1β-targeting agents in NSCLC and consider how they may be used in clinical practice if approved View All Lung Cancer touchTALKS A moving target: Assessing the role of EGFR-TKIs in early-stage NSCLC Dr Stephen Liu Watch Time: 27 mins Available in: Dr Stephen Liu presents the latest data and future directions of targeted therapy within the rapidly evolving treatment landscape for patients with early-stage NSCLC. Learning objectives Learning Objectives Recall the latest efficacy and safety data for EGFR-TKIs for patients with early-stage EGFR-mutant NSCLC Describe how the evolving use of EGFR-TKIs may impact the current recommendations for mutation testing in NSCLC Discuss how EGFR-TKIs may be incorporated into the evolving treatment pathway for early-stage NSCLC, now and in the future View All Bladder Cancer, Genitourinary Cancers Alison Birtle, ASCO GU 2021: Peri-operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer Alison Birtle touchONCOLOGY joins Dr Alison Birtle (Consultant Oncologist and Honorary Senior Lecturer, Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK) to discuss the updated primary and secondary analysis of the POUT trial in upper tract urothelial cancer (ClinicalTrials.gov Identifier: NCT01993979). The abstract “Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance [ ] View All Gastrointestinal Oncology Jean-Luc Van Laethem, ASCO GI 2021: Results of the KEYNOTE-224 Study We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) about the efficacy and safety findings of the KEYNOTE-224 study (Clinical Trial Identifier: NCT02702414). The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at the [ ] View All Breast Cancer Sara Tolaney, St. Gallen Breast Cancer Conference 2021: Patient-reported outcomes from MonarchE Sara Tolaney, Dr Sara Tolaney (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA) joins touchONCOLOGY to discuss the patient-reported health-related quality-of-life outcomes data from the MonarchE trial (ClinicalTrials.gov Identifier: NCT03155997) in patients with HR+, HER2- breast cancer being treated with abemaciclib plus endocrine therapy. The e-poster ‘Patients’ quality of life and side effect perceptions in monarchE, [ ] View All Prostate Cancer Axel Merseburger, ASCO GU 2021: Apalutamide in Metastatic Castration-sensitive Prostate Cancer Axel Merseburger We were delighted to talk to Editor-in-Chief Prof. Axel Merseburger (Professor and Chairman, Department of Urology, University of Lübeck, Lübeck, Germany) around the TITAN trial in metastatic castration-sensitive prostate cancer (ClinicalTrials.gov Identifer: NCT02489318). The abstract “Final analysis results from TITAN: A phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic [ ] View All Gastrointestinal Oncology Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma Mao Okada, Shun Yamamoto, Ken Kato Oncology Hematology Review. 2020;16(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.16.2.90 Esophageal cancer is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide.1 The main histological subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common subtype, and the frequency of this disease is highest in Eastern Asia and Eastern Africa.2 In Western countries, however, the incidence [ ] View All Multiple Myeloma Latest Developments in Cellular Therapy for Multiple Myeloma Tara K Gregory, Henning Schade, Jesús G Berdeja Oncology Hematology Review (US). 2020;16(2):111-8 DOI: https://doi.org/10.17925/OHR.2021.16.2.111 Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable [ ] View All Sarcoma Pexidartinib and CSF1R Inhibitors as Treatment for Tenosynovial Giant Cell Tumors Caroline J Granger, Ty Subhawong, Gina D’Amato Oncology Hematology Review (US). 2020;16(2):119-23 DOI: https://doi.org/10.17925/OHR.2021.16.2.119 Tenosynovial giant cell tumor (TGCT)—previously referred to as giant cell tumor of the tendon sheath or pigmented villonodular synovitis (PVNS)—is a largely benign, rare, proliferative lesion arising from the synovial lining of joints, bursae, and tendon sheaths.1 This review serves to discuss the epidemiology, molecular biology, clinical behavior, and the current treatment modalities of TGCT that [ ] View All Bladder Cancer Evolving Therapies for Urothelial Carcinoma—Novel Paradigms and Future Directions Madison Williams, Ryan Williams, Daruka Mahadevan Oncology Hematology Review. 2020;16(2):82-9 DOI: https://doi.org/10.17925/OHR.2021.16.2.82 Urothelial carcinoma is the most common histologic type of bladder cancer in the USA and Europe, accounting for 90% of all bladder cancers. It is the sixth most common type of cancer diagnosed in the USA, and the 10th leading cause of cancer death, with an estimated 17,980 deaths predicted in 2020.1 Although the 5-year survival [ ] View All Gynaecological Oncology, Ovarian Cancer touchCONGRESS PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice Dr Alexandra Leary, Prof. Keiichi Fujiwara, Prof. Nicoletta Colombo Watch Time: 61 mins Available in: Watch this two-part activity exploring recent developments on the use of PARP inhibitors as first-line maintenance therapy in ovarian cancer. Filmed following the SGO Virtual Annual Meeting 2021.Part 1: Watch gynaecological cancer expert Dr Alexandra Leary review key data from the SGO Virtual Annual Meeting 2021 Watch NowPart 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview Learning objectives Learning Objectives Recall the latest data for PARP inhibitors for first-line maintenance treatment and how they may impact clinical practice Describe the latest safety data for the PARP inhibitors Define the different factors that influence treatment selection of PARP inhibitor therapy in the first-line maintenance setting Immunotherapy, Lung Cancer touchPANEL DISCUSSION Targeting IL-1β in NSCLC: What does the future hold? Dr Pilar Garrido, Dr Barbara Melosky, Dr Alastair Greystoke Watch Time: 30 mins Available in: Watch a panel of experts discuss immunotherapy for non-small cell lung cancer (NSCLC) and the possible future role of interleukin-1β (IL-1β) blockade. Learning objectives Learning Objectives Discuss the use of checkpoint inhibitors as immunotherapy for NSCLC and recognize their limitations Recall the rationale for targeting IL-1β in cancer immunotherapy and the IL-1β-targeted agents currently in clinical development for solid tumours Describe the clinical trials and data for IL-1β-targeting agents in NSCLC and consider how they may be used in clinical practice if approved More From The Conference Hub View All View highlights and coverage from leading international Oncology congresses Latest Journal Articles View All Read the latest articles from our peer reviewed Oncology journals published by touchONCOLOGY COVID-19 COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukaemia: What Can We Expect? Mohammad Ammad Ud Din, Saad Jamshed touchREVIEWS in Oncology Haematology. 2021;17(1):Online ahead of journal publication Advanced age and other comorbid conditions put patients with chronic lymphocytic leukaemia (CLL) at an increased risk of morbidity and mortality from SARS-CoV-2 infection, with early studies showing case fatality rates of over 30% in patients with CLL with symptomatic COVID-19.1,2 As the vaccination against COVID-19 is becoming available for use in the general population, its [ ] Haematology FOREWORD – ONCOLOGY HEMATOLOGY (US) – VOLUME 16 ISSUE 2– FALL 2020 Welcome to the latest edition of Oncology Hematology Review, which contains a wide range of articles reflecting the scope of this field. We begin with an article on the subject of urothelial cancer, whose treatment landscape has been transformed in recent years by the availability of immune checkpoint inhibitors. Williams et al. review the role [ ] Sarcoma Pexidartinib and CSF1R Inhibitors as Treatment for Tenosynovial Giant Cell Tumors Caroline J Granger, Ty Subhawong, Gina D’Amato Oncology Hematology Review (US). 2020;16(2):119-23 DOI: https://doi.org/10.17925/OHR.2021.16.2.119 Tenosynovial giant cell tumor (TGCT)—previously referred to as giant cell tumor of the tendon sheath or pigmented villonodular synovitis (PVNS)—is a largely benign, rare, proliferative lesion arising from the synovial lining of joints, bursae, and tendon sheaths.1 This review serves to discuss the epidemiology, molecular biology, clinical behavior, and the current treatment modalities of TGCT that [ ] Multiple Myeloma Latest Developments in Cellular Therapy for Multiple Myeloma Tara K Gregory, Henning Schade, Jesús G Berdeja Oncology Hematology Review (US). 2020;16(2):111-8 DOI: https://doi.org/10.17925/OHR.2021.16.2.111 Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable [ ] Want To Know More About Our Journals? Taking a balanced and practical view of the current clinical landscape in Oncology is at the heart of touchONCOLOGY and the journals we produce. The European Oncology & Haematology and Oncology & Hematology Review (US) are free-to-access, peer reviewed journals that aim to provide balanced and objective articles relevant to the day-to-day clinical setting. Learn more about our journals Society Congress Partners View All touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down Clicky Media Logoconsultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72

TAGS:Education Online touchONCOLOGY 

<<< Thank you for your visit >>>

touchONCOLOGY provides peer-reviewed articles and multimedia content on cancer risk, diagnosis and treatment for oncology professionals.

Hot Websites